Barclays PLC Increases Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Barclays PLC raised its position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 677.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,943 shares of the company’s stock after purchasing an additional 18,249 shares during the quarter. Barclays PLC’s holdings in Outlook Therapeutics were worth $111,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OTLK. Great Point Partners LLC raised its position in Outlook Therapeutics by 15.0% in the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after purchasing an additional 221,510 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Outlook Therapeutics during the second quarter worth $303,000. XTX Topco Ltd purchased a new stake in shares of Outlook Therapeutics during the third quarter worth $199,000. Squarepoint Ops LLC purchased a new stake in shares of Outlook Therapeutics during the second quarter worth $232,000. Finally, State Street Corp increased its position in shares of Outlook Therapeutics by 10.0% during the third quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after acquiring an additional 21,201 shares during the period. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Price Performance

NASDAQ:OTLK opened at $2.18 on Thursday. The firm has a market capitalization of $54.30 million, a PE ratio of -0.20 and a beta of 0.53. The business’s fifty day moving average price is $3.33 and its 200 day moving average price is $5.61. Outlook Therapeutics, Inc. has a 12 month low of $0.87 and a 12 month high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last posted its earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.06. As a group, equities analysts anticipate that Outlook Therapeutics, Inc. will post -3.84 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research report on Friday, November 29th. Finally, BTIG Research cut their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 29th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.73.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.